Genitourinary Cancers

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

A211901

Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

EAY191

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

A Randomized Trial of Neratinib, A Pan-ErbB Inhibitor, Alone or in Combination with Palbociclib, A CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors - A ComboMATCH Treatment Trial

GRAIL-MA-002

REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

NRG-CC014

Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

NRG-GU013

THE PHASE III HIGH FIVE TRIAL FIVE FRACTION RADIATION FOR HIGH-RISK PROSTATE CANCER

NRG-GU014

Randomized Phase II Trial of Pembrolizumab and Radiation vs Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC)

S1802

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature

S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)